Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma

Leukemia

Volumn 29, Issue 3, 2015, Pages 715-726

  Yang, Y ^a,b,g   Chen, Y ^a,b,c   Saha, M N ^a,b   Chen, J ^d   Evans, K ^d   Qiu, L ^e   Reece, D ^f   Chen, G A ^c   Chang, H ^a,b,c,f  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NANCHANG UNIVERSITY   (China)

^d Ontario Cancer Biomarker Network   (Canada)

^e INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^f TORONTO GENERAL HOSPITAL   (Canada)

^g Novade Pharmaceutical Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DEXAMETHASONE; ENZASTAURIN; MARCKS PROTEIN; S PHASE KINASE ASSOCIATED PROTEIN 2; TRANSCRIPTION FACTOR E2F1; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; CDK2 PROTEIN, MOUSE; CDKN1B PROTEIN, MOUSE; CYCLIN E; E2F1 PROTEIN, MOUSE; INDOLE DERIVATIVE; MEMBRANE PROTEIN; MYRISTOYLATED ALANINE-RICH C KINASE SUBSTRATE; PYRAZINE DERIVATIVE; S PHASE KINASE ASSOCIATED PROTEIN; SIGNAL PEPTIDE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG RESISTANCE; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CELL CYCLE; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; MOUSE; PATHOLOGY; PHOSPHORYLATION; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; SURVIVAL; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL CYCLE; CELL LINE, TUMOR; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; E2F1 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MICE; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PRIMARY CELL CULTURE; PYRAZINES; RNA, SMALL INTERFERING; S-PHASE KINASE-ASSOCIATED PROTEINS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

EID: 84924423307     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.255     Document Type: Article

References (37)

1. Anderson KC. Oncogenomics to target myeloma in the bone marrow microenvironment. Clin Cancer Res 2011; 17: 1225-1233.
2. Dimopoulos MA, San-Miguel JF, Anderson KC. Emerging therapies for the treatment of relapsed or refractory multiple myeloma. Eur J Haematol 2011; 86: 1-15.
3. Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel DS. Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 1999; 93: 3044-3052.
4. Ni H, Ergin M, Huang Q, Qin JZ, Amin HM, Martinez RL et al. Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. Br J Haematol 2001; 115: 279-286.
5. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007; 12: 131-144.
6. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U et al. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 2007; 109: 2293-2302.
7. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9: 1136-1144.
8. Markovina S, Callander NS, O'Connor SL, Kim J, Werndli JE, Raschko M et al. Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res 2008; 6: 1356-1364.
9. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W et al. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood 2012; 120: 3260-3270.
10. Moschetta M, Basile A, Ferrucci A, Frassanito MA, Rao L, Ria R et al. Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma. Clin Cancer Res 2013; 19: 4371-4382.
11. Zhou W, Yang Y, Xia J, Wang H, Salama ME, Xiong W et al. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell 2013; 23: 48-62.
12. Gatlin JC, Estrada-Bernal A, Sanford SD, Pfenninger KH. Myristoylated, alanine-rich C-kinase substrate phosphorylation regulates growth cone adhesion and pathfinding. Mol Biol Cell 2006; 17: 5115-5130.
13. Micallef J, Taccone M, Mukherjee J, Croul S, Busby J, Moran MF et al. Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression. Cancer Res 2009; 69: 7548-7556.
14. Rombouts K, Lottini B, Caligiuri A, Liotta F, Mello T, Carloni V et al. MARCKS is a downstream effector in platelet-derived growth factor-induced cell motility in activated human hepatic stellate cells. Exp Cell Res 2008; 314: 1444-1454.
15. Hartwig JH, Thelen M, Rosen A, Janmey PA, Nairn AC, Aderem A. MARCKS is an actin filament crosslinking protein regulated by protein kinase C and calcium-calmodulin. Nature 1992; 356: 618-622.
16. Blackshear PJ. The MARCKS family of cellular protein kinase C substrates. J Biol Chem 1993; 268: 1501-1504.
17. Aderem A. The MARCKS brothers: a family of protein kinase C substrates. Cell 1992; 71: 713-716.
18. Estrada-Bernal A, Gatlin JC, Sunpaweravong S, Pfenninger KH. Dynamic adhesions and MARCKS in melanoma cells. J Cell Sci 2009; 122: 2300-2310.
19. Podar K, Raab MS, Zhang J, McMillin D, Breitkreutz I, Tai YT et al. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood 2007; 109: 1669-1677.
20. Raab MS, Breitkreutz I, Tonon G, Zhang J, Hayden PJ, Nguyen T et al. Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. Blood 2009; 113: 1513-1521.
21. Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 2010; 116: 2543-2553.
22. Podar K, Raab MS, Chauhan D, Anderson KC. The therapeutic role of targeting protein kinase C in solid and hematologic malignancies. Expert Opin Investig Drugs 2007; 16 : 1693-1707.
23. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005; 106: 296-303.
24. Chen CH, Thai P, Yoneda K, Adler KB, Yang PC, Wu R. A peptide that inhibits function of myristoylated alanine-rich C kinase substrate (MARCKS) reduces lung cancer metastasis. Oncogene 2013; 33: 3696-3706.
25. Teicher BA. Protein kinase C as a therapeutic target. Clin Cancer Res 2006; 12: 5336-5345.
26. Roffey J, Rosse C, Linch M, Hibbert A, McDonald NQ, Parker PJ. Protein kinase C intervention: the state of play. Curr Opin Cell Biol 2009; 21: 268-279.
27. Buzzeo R, Enkemann S, Nimmanapalli R, Alsina M, Lichtenheld MG, Dalton WS et al. Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341. Clin Cancer Res 2005; 11: 6057-6064.
28. Ott LE, Sung EJ, Melvin AT, Sheats MK, Haugh JM, Adler KB et al. Fibroblast migration is regulated by myristoylated alanine-rich C-kinase substrate (MARCKS) protein. PLoS One 2013; 8: e66512.
29. Zhang L, Wang C. F-box protein Skp2: a novel transcriptional target of E2F. Oncogene 2006; 25: 2615-2627.
30. Salon C, Merdzhanova G, Brambilla C, Brambilla E, Gazzeri S, Eymin B. E2F-1, Skp2 and cyclin E oncoproteins are upregulated and directly correlated in high-grade neuroendocrine lung tumors. Oncogene 2007; 26: 6927-6936.
31. Walker BA, Leone PE, Jenner MW, Li C, Gonzalez D, Johnson DC et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood 2006; 108: 1733-1743.
32. Stephens OW, Zhang Q, Qu P, Zhou Y, Chavan S, Tian E et al. An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification. Blood 2012; 119: 503-512.
33. Zhan F, Colla S, Wu X, Chen B, Stewart JP, Kuehl WM et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood 2007; 109: 4995-5001.
34. Chen Q, Xie W, Kuhn DJ, Voorhees PM, Lopez-Girona A, Mendy D et al. Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood 2008; 111: 4690-4699.
35. Chan CH, Morrow JK, Li CF, Gao Y, Jin G, Moten A et al. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell 2013; 154: 556-568.
36. Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer 2009; 9: 785-797.
37. Jarboe JS, Anderson JC, Duarte CW, Mehta T, Nowsheen S, Hicks PH et al. MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for glioma. Clin Cancer Res 2012; 18: 3030-3041.